01681.HK
Consun Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 15.25
+0.73%Year over year
Reported trailing growth
- Revenue
- +10.5%
- EBITDA
- +19.5%
- EBIT
- +15.2%
- EPS
- +16.9%
- Free cash flow
- +34.5%
- Operating cash flow
- +31.0%
Forward estimates
Based on analyst estimates
- Revenue
- -48.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +13.5%
- EBITDA
- +15.5%
- EBIT
- +16.7%
- Net income
- +16.4%
- EPS
- +13.6%
- Free cash flow
- +8.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026